Sanofi has struck a $9.5 billion deal to buy Blueprint Medicines for an approved rare disease drug and an early-stage immunology pipeline. The deal, $9.1 billion of which is upfront, will give Sanofi ...

French pharmaceutical company Sanofi said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local partner Vietnam Vaccine Company (VNVC), which ...

The basics: Sanofi relocates 2,000 employees to new $130M Morristown flagship M Station West features nature-inspired, people-focused design Includes coworking space, employee clinic, rooftop terrace ...

Sanofi SAN 0.23% said it entered an agreement to acquire Vigil Neuroscience VIGL 0.00% for approximately $470 million, a deal that adds a new investigational treatment for Alzheimer’s disease to ...

Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Ph ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

In the 14-week phase 2b study by Sanofi and Teva's U.S. affiliate held in the U.S., Europe and Israel, the drug, called duvakitug, showed that 36.2% of low dose and 47.8% of high dose patients ...

Last month, French big pharma Sanofi and British drug discovery biotech Healx partnered to address rare diseases. Only around 5% of rare diseases have an approved treatment, so speeding up the drug ...

Sanofi plans to roll out the model to most hospitals, including critical access and disproportionate share hospitals, on Jan. 6. Health centers will be folded in on March 1.

In addition to its pharma partnership, Healx is also working on its own pipeline of medicines. This past August, the company raised $47 million in a Series C round that was co-led by R42 Group and ...